Bringing parity to infertility, with Jean Duvall

Male infertility accounts for about 50% of infertility struggles, but research spending for men accounts for just 7%. That’s according to Jean Duvall, CEO of Repronovo, a company that’s working on new infertility treatments for men and women.

At the Biotech Showcase during JP Morgan week in San Francisco, editor-in-chief Jonah Comstock sat down with Duvall to discuss the existing institutional biases in the infertility space and what Repronovo is doing to make a change.

Their products in development include an oral treatment for low testosterone and low sperm count, as well as a therapy for adenomyosis, a driver of infertility in women.

Duvall discusses the status quo in infertility and the benefits a wider range of therapies would have for couples trying to conceive, gives an update on her company’s progress, and shares some of her impressions from the biggest week in biotech.

Check out the video for the full interview and tune into other conversations from JPM2026 here.